Pulmonx (LUNG) FDA Approvals $2.59 -0.21 (-7.50%) As of 11:39 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Pulmonx's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Pulmonx (LUNG). Over the past two years, Pulmonx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as AeriSeal. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. AeriSeal FDA Regulatory Events AeriSeal is a drug developed by Pulmonx for the following indication: For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Publication - November 17,2026Publication Drug: AeriSealAnnounced Date: November 17, 2026Indication: For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation. AnnouncementPulmonx Corporation announced the online publication of results from the CONVERT Trial evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation, in Respiration: International Journal of Thoracic Medicine.AI SummaryPulmonx Corporation announced the online publication of results from the CONVERT Trial in Respiration: International Journal of Thoracic Medicine. The study tested whether the AeriSeal System could seal channels between lung lobes in people with severe emphysema and collateral ventilation. These channels can prevent Zephyr Endobronchial Valves from reducing the volume of a targeted lobe. The trial included 101 patients at 14 sites in Europe and Australia. Among 99 evaluable patients, 75 (75.8%) had a treated lobe converted from collateral ventilation-positive to collateral ventilation-negative status. Patients who converted then received Zephyr Valves. At 45 days, 88.9% of evaluable patients had a clinically meaningful reduction in target-lobe volume, which continued through 12 months. Patients also showed improvements in lung function, hyperinflation, quality of life, and breathlessness. Pulmonx said the findings suggest AeriSeal may help more people with severe emphysema become candidates for valve treatment. The company is enrolling patients in the international CONVERT II study, which will further assess AeriSeal’s safety and effectiveness.Read Announcement Pulmonx FDA Events - Frequently Asked Questions Has Pulmonx received FDA approval? As of now, Pulmonx (LUNG) has not received any FDA approvals for its therapy in the last two years. What drugs has Pulmonx submitted to the FDA? In the past two years, Pulmonx (LUNG) has reported FDA regulatory activity for AeriSeal. What is the most recent FDA event for Pulmonx? The most recent FDA-related event for Pulmonx occurred on November 17, 2026, involving AeriSeal. The update was categorized as "Publication," with the company reporting: "Pulmonx Corporation announced the online publication of results from the CONVERT Trial evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation, in Respiration: International Journal of Thoracic Medicine." What conditions do Pulmonx's current drugs treat? Currently, Pulmonx has one therapy (AeriSeal) targeting the following condition: For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events ACADIA Pharmaceuticals FDA EventsEikon Therapeutics FDA EventsIonis Pharmaceuticals FDA EventsKaryopharm Therapeutics FDA EventsPulmonx FDA EventsMetaVia FDA EventsNeonc Technologies FDA EventsRegeneron Pharmaceuticals FDA EventsSELLAS Life Sciences Group FDA EventsSanofi FDA EventsVeru FDA EventsMedtronic FDA EventsAclaris Therapeutics FDA EventsBioVie FDA EventsBioLineRx FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies NeuroPace FDA Events Brainsway FDA Events Mobia Medical FDA Events SS Innovations International FDA Events Orchestra BioMed FDA Events Treace Medical Concepts FDA Events ClearPoint Neuro FDA Events Profound Medical FDA Events KORU Medical Systems FDA Events Apyx Medical FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:LUNG last updated on 11/17/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Publication - November 17,2026Publication Drug: AeriSealAnnounced Date: November 17, 2026Indication: For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation. AnnouncementPulmonx Corporation announced the online publication of results from the CONVERT Trial evaluating the AeriSeal® System in patients with severe emphysema and collateral ventilation, in Respiration: International Journal of Thoracic Medicine.AI SummaryPulmonx Corporation announced the online publication of results from the CONVERT Trial in Respiration: International Journal of Thoracic Medicine. The study tested whether the AeriSeal System could seal channels between lung lobes in people with severe emphysema and collateral ventilation. These channels can prevent Zephyr Endobronchial Valves from reducing the volume of a targeted lobe. The trial included 101 patients at 14 sites in Europe and Australia. Among 99 evaluable patients, 75 (75.8%) had a treated lobe converted from collateral ventilation-positive to collateral ventilation-negative status. Patients who converted then received Zephyr Valves. At 45 days, 88.9% of evaluable patients had a clinically meaningful reduction in target-lobe volume, which continued through 12 months. Patients also showed improvements in lung function, hyperinflation, quality of life, and breathlessness. Pulmonx said the findings suggest AeriSeal may help more people with severe emphysema become candidates for valve treatment. The company is enrolling patients in the international CONVERT II study, which will further assess AeriSeal’s safety and effectiveness.Read Announcement